dronedarone (Multaq)

From Aaushi
Jump to navigation Jump to search

Introduction

Formerly Class III antiarrhythmic agent.[10]

Indications

* less effective than amiodarone, avoid[12]

Contraindications

Adverse effects

Mechanism of action

Clinical trials

see ATHENA study

Notes

costs over $200/month (2009)[4]

More general terms

Additional terms

References

  1. 1.0 1.1 Kober L et al for the Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008, 358:2678 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18565860
  2. Hohnloser SH et al for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009 Feb 12; 360:668 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19213680
  3. 3.0 3.1 3.2 Zimetbaum PJ. Dronedarone for atrial fibrillation-an odyssey. N Engl J Med. 2009 Apr 30;360(18):1811-3. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19403901
  4. 4.0 4.1 Prescriber's Letter 16(8): 2009 COMMENTARY: New Drug: Multaq (Dronedarone) GUIDELINES: Management of Patients with Atrial Fibrillation (ACC/AHA/ESC 2006) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=250807&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. FDA MedWatch, Jan 14, 2011 Multaq (dronedarone) - Drug Safety Communication: Risk of Severe Liver Injury http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm240110.htm
  6. 6.0 6.1 6.2 Sanofi Provides Multaq Phase IIIb PALLAS Trial Update
    Indication seeking trial in permanent AF patient population stopped - Benefit-risk of Multaq remains unchanged in non-permanent AF patients - http://en.sanofi.com/binaries/20110707_PALLAS_en_tcm28-33021.pdf
  7. 7.0 7.1 7.2 FDA MedWatch: 07/21/2011 Multaq (dronedarone): Drug Safety Communication - Increased Risk of Death or Serious Cardiovascular Events http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm264204.htm
  8. 8.0 8.1 Prescriber's Letter 18(10): 2011 Multaq (Dronedarone) Alternatives for Atrial Fibrillation Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=271009&pb=PRL (subscription needed) http://www.prescribersletter.com
  9. Connolly SJ et al. for the PALLAS Investigators. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011 Dec 15;365(24):2268-76. Epub 2011 Nov 14. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22082198
    Nattel S. Dronedarone and atrial fibrillation - Jekyll and Hyde? N Engl J Med. 2011 Dec 15;365(24):2321-2. Epub 2011 Nov 14 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22082122
  10. 10.0 10.1 10.2 10.3 10.4 Medical Knowledge Self Assessment Program (MKSAP) 16, 17. American College of Physicians, Philadelphia 2012, 2015
  11. Patel C, Yan GX, Kowey PR. Dronedarone. Circulation. 2009 Aug 18;120(7):636-44. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19687370
  12. 12.0 12.1 Therapeutics Letter #108. Therapeutics Initiative Drugs to Avoid. http://www.ti.ubc.ca/2018/01/04/108-drugs-avoid/

Database